The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
Open accessAbstract
Myeloid-derived suppressor cells (MDSCs) contribute to tumor-mediated immune escape and negatively correlate with overall survival of cancer patients. Nowadays, a variety of methods to target MDSCs are being investigated. Based on the intervention stage of MDSCs, namely development, expansion and activation, function and turnover, these methods can be divided into: (I) prevention or differentiation to mature cells, (II) blockade of MDSC expansion and activation, (III) inhibition of MDSC suppressive activity or (IV) depletion of intratumoral MDSCs. This review describes effective mono- or multimodal-therapies that target MDSCs for the benefit of cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 4×
“Strategies that inhibit nutrient depletion MDSCs can deplete nutrients needed for the synthesis of lymphocyte-activating proteins.(6) For instance, MDSCs can deplete L-arginine(44) and L-cysteine,(45) 2 amino acids required for T-cell differentiation.”
BackgroundInfluentialHeissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N. R., Crystal, R. G., Besmer, P., Lyden, D., Moore, M. A. S., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00754-7 · Cited by 1,751
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 2×
“In the last decade, several studies have reported that local tumor irradiation can enhance immunotherapy efficacy, either by increasing localized APC uptake of tumor antigens or by enhancing intratumoral migration of immunization-induced antigen-specific CTLs.78,79 Also, addition of sunitinib to low-dose local tumor i…”
BackgroundMyeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Foell, D., Wittkowski, H., Vogl, T., & Roth, J. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306170 · Cited by 879
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 766
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 650
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637 · cited 1×
“ROS levels could also be reduced by synthetic triterpenoids, such as bardoxolone methyl (CDDO-Me), via upregulation of antioxidant genes.(57) In higher concentrations CDDO-Me also inhibited STAT3.”
BackgroundMirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 564
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Sansone, P., & Bromberg, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8907 · Cited by 515
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma
Ochoa, A. C., Zea, A. H., Hernandez, C., & Rodriguez, P. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2197 · Cited by 489
Pan, P.-Y., Ma, G., Weber, K. J., Ozao-Choy, J., Wang, G., Yin, B., Divino, C. M., & Chen, S.-H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1882 · Cited by 467
Kusmartsev, S. A., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E. M., Lush, R. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 460
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D., & Ostrand-Rosenberg, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804253 · Cited by 427
Mechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells
Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2593 · Cited by 423
Welte, T., Zhang, S. S. M., Wang, T., Zhang, Z., Hesslein, D. G. T., Yin, Z., Kano, A., Iwamoto, Y., Li, E., Craft, J. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237137100 · Cited by 381 · cited 1×
“showed that transgenic mice with a STAT3 deletion in the bone marrow died within 2 months of a Crohn’s disease-like inflammatory syndrome.(41)”
BackgroundLesokhin, A. M., Hohl, T. M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G. A., Lazarus, J. J., Pamer, E. G., Houghton, A. N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1792 · Cited by 378
Le, H. K., Graham, L., Cha, E., Morales, J. K., Manjili, M. H., & Bear, H. D. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.03.015 · Cited by 368
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice
Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J. E., Abe, J., Shono, Y., Kitabatake, M., Kakimi, K., Mukaida, N., et al. (2008) · Blood · doi:10.1182/blood-2008-01-136895 · Cited by 367
Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z., & Colombo, M. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1882 · Cited by 329
Pan, P.-Y., Wang, G. X., Yin, B., Ozao, J., Ku, T., Divino, C. M., & Chen, S.-H. (2008) · Blood · doi:10.1182/blood-2007-04-086835 · Cited by 319
IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V., Mocellin, S., Zanon, A., Rossi, C. R., Nitti, D., Bronte, V., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803831 · Cited by 304
Ko, J. S., Rayman, P., Ireland, J., Swaidani, S., Li, G., Bunting, K. D., Rini, B., Finke, J. H., & Cohen, P. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3278 · Cited by 296
Veltman, J. D., Lambers, M. E., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G., & Hegmans, J. P. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-464 · Cited by 291
De Santo, C., Serafini, P., Marigo, I., Dolcetti, L., Bolla, M., Del Soldato, P., Melani, C., Guiducci, C., Colombo, M. P., Iezzi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409783102 · Cited by 284
Porembka, M. R., Mitchem, J. B., Belt, B. A., Hsieh, C.-S., Lee, H.-M., Herndon, J., Gillanders, W. E., Linehan, D. C., & Goedegebuure, P. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1178-0 · Cited by 277
Kusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.346 · Cited by 276
Emerging Tim-3 functions in antimicrobial and tumor immunity
Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C., & Kuchroo, V. K. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.003 · Cited by 258
Shirota, Y., Shirota, H., & Klinman, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101304 · Cited by 257
Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S. C., Rao, S. S., Qian, J., Hailemichael, Y., Nurieva, R., Dwyer, K. C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3560 · Cited by 233
Kawarada, Y., Ganss, R., Garbi, N., Sacher, T., Arnold, B., & Hämmerling, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5247 · Cited by 220
Therapeutic targeting of myeloid-derived suppressor cells
Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., & Bronte, V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.014 · Cited by 206
Ko, H.-J., Kim, Y.-J., Kim, Y.-S., Chang, W.-S., Ko, S.-Y., Chang, S.-Y., Sakaguchi, S., & Kang, C.-Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4639 · Cited by 203
Amato, R. J., Hawkins, R. E., Kaufman, H. L., Thompson, J. A., Tomczak, P., Szczylik, C., McDonald, M., Eastty, S., Shingler, W. H., de Belin, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2082 · Cited by 199
Heckelsmiller, K., Rall, K., Beck, S., Schlamp, A., Seiderer, J., Jahrsdörfer, B., Krug, A., Rothenfusser, S., Endres, S., & Hartmann, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3892 · Cited by 194
Fricke, I., Mirza, N., Dupont, J., Lockhart, C., Jackson, A., Lee, J.-H., Sosman, J. A., & Gabrilovich, D. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0409 · Cited by 182
Aptamer-Mediated Blockade of IL4Rα Triggers Apoptosis of MDSCs and Limits Tumor Progression
Roth, F., De La Fuente, A. C., Vella, J. L., Zoso, A., Inverardi, L., & Serafini, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2772 · Cited by 173
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.
Seung, L. P., Rowley, D. A., Dubey, P., & Schreiber, H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6254 · Cited by 170
Zhou, J., Wu, J., Chen, X., Fortenbery, N., Eksioglu, E., Kodumudi, K. N., PK, E.-B., Dong, J., Djeu, J. Y., & Wei, S. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.007 · Cited by 167
Tu, S. P., Jin, H., Shi, J. D., Zhu, L. M., Suo, Y., Lu, G., Liu, A., Wang, T. C., & Yang, C. S. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0247 · Cited by 165
Vitamin A deficiency in mice causes a systemic expansion of myeloid cells
Kuwata, T., Wang, I., Tamura, T., Ponnamperuma, R. M., Levine, R., Holmes, K. L., Morse, H. C., Luca, L. M. D., & Ozato, K. (2000) · Blood · doi:10.1182/blood.v95.11.3349 · Cited by 159
Bose, A., Taylor, J. L., Alber, S. M., Watkins, S. C., García, J. A., Rini, B. I., Ko, J. S., Cohen, P. A., Finke, J. H., & Storkus, W. J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25863 · Cited by 150
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion
Talmadge, J. E., Hood, K. C., Zobel, L., Shafer, L. R., Coles, M., & Tóth, B. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.09.021 · Cited by 139
Farsaci, B., Higgins, J. P., & Hodge, J. W. (2011) · International Journal of Cancer · doi:10.1002/ijc.26219 · Cited by 127
Bill, M. A., Fuchs, J. R., Li, C., Yui, J. C., Bakan, C. E., Benson, D. M., Schwartz, E. B., Abdelhamid, D. S., Lin, J., Hoyt, D. G., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-165 · Cited by 121
Testa, U., Masciulli, R., Tritarelli, E., Pustorino, R., Mariani, G., Martucci, R., Barberi, T., CAMAGNA, A., Valtieri, M., & Peschle, C. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.6.2418 · Cited by 107
Kodera, Y., Katanasaka, Y., Kitamura, Y., Tsuda, H., Nishio, K., Tamura, T., & Koizumi, F. (2011) · Breast Cancer Research · doi:10.1186/bcr2903 · Cited by 107
The growing diversity and spectrum of action of myeloid‐derived suppressor cells
Mantovani, A. (2010) · European Journal of Immunology · doi:10.1002/eji.201041170 · Cited by 96
Myeloid derived suppressor cells: Targets for therapy
Waldron, T. J., Quatromoni, J. G., Karakasheva, T. A., Singhal, S. K., & Rustgi, A. K. (2013) · OncoImmunology · doi:10.4161/onci.24117 · Cited by 86
Sinha, P., & Ostrand‐Rosenberg, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1470-2 · Cited by 73
Lü, P., Yu, B., & Xu, J. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1219 · Cited by 73
Konopleva, M. Y., Zhang, W., Shi, Y.-X., McQueen, T. J., Tsao, T., Abdelrahim, M., Munsell, M. F., Johansen, M. J., Yu, D., Madden, T. L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0350 · Cited by 70
Walkley, C. R., Yuan, Y.-D., Chandraratna, R., & McArthur, G. A. (2002) · Leukemia · doi:10.1038/sj.leu.2402625 · Cited by 60
Wu, H., Tao, N., Liu, X., Xiao, L., Tang, J., Ma, C., Xu, X., Shao, H., Hou, B., Wang, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051751 · Cited by 57
Muralikrishnan, G., Dinda, A. K., & Shakeel, F. (2010) · Immunological Investigations · doi:10.3109/08820139.2010.487083 · Cited by 52
Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination
Draghiciu, O., Walczak, M., Hoogeboom, B. N., Franken, K. L. M. C., Melief, K., Nijman, H. W., & Daemen, T. (2013) · International Journal of Cancer · doi:10.1002/ijc.28418 · Cited by 47
Self-citationMa, J., Liu, Y., Li, Y., Gu, J. H., Liu, J., Tang, J., Wang, J., Ryffel, B., Shen, Y., Brand, D. D., et al. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0513297 · Cited by 45
Nakashima, H., Terabe, M., Berzofsky, J. A., Husain, S. R., & Puri, R. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102095 · Cited by 34
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma
D’Amico, R. S., Lei, L., Kennedy, B. C., Sisti, J. S., Ebiana, V., Crisman, C., Christensen, J. G., Gil, O. D., Rosenfeld, S. S., Canoll, P., et al. (2012) · Neurological Research · doi:10.1179/1743132812y.0000000005 · Cited by 20
Cited by
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
“These cells contribute to tumor immune escape by inhibiting cytotoxic T-cell proliferation and driving Treg induction (3, 9, 10).”
BackgroundTumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Metadata
- Authors
- Draghiciu, O., Lubbers, J., Nijman, H. W., & Daemen, T.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2015-01-02
- Volume
- 4
- Issue
- 1
- Pages
- e954829
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2051355795
- Cited by
- 274
- References
- 79
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.